Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma

Autor: Otto C. Boerman, Frans H.M. Corstens, J.M.M. Raemaekers, David M. Goldenberg, Wim J.G. Oyen, Cathelijne Frielink, Ernst J. Postema
Rok vydání: 2003
Předmět:
Cancer Research
Pathology
Time Factors
Lymphoma
Sialic Acid Binding Ig-like Lectin 2
medicine.medical_treatment
Lutetium
Kidney
Iodine Radioisotopes
Mice
Lectins
Neoplasms
Tumor Cells
Cultured
Tissue Distribution
Yttrium Radioisotopes
Femur
Lung
Mice
Inbred BALB C
biology
Muscles
Antibodies
Monoclonal
General Medicine
Rhenium
medicine.anatomical_structure
Liver
Oncology
Radioimmunotherapy
Female
Antibody
medicine.drug
Biodistribution
medicine.medical_specialty
Duodenum
medicine.drug_class
Mice
Nude
Antibodies
Monoclonal
Humanized
Monoclonal antibody
Antigen
Antigens
CD
medicine
Animals
Humans
Radiology
Nuclear Medicine and imaging
Radioisotopes
Pharmacology
Analysis of Variance
business.industry
Immunotherapy
gene therapy and transplantation [UMCN 1.4]
medicine.disease
Xenograft Model Antitumor Assays
Antigens
Differentiation
B-Lymphocyte
biology.protein
Cancer research
Bone marrow
business
Cell Adhesion Molecules
Epratuzumab
Neoplasm Transplantation
Spleen
Zdroj: Cancer Biotherapy & Radiopharmaceuticals, 18, 4, pp. 525-33
Cancer Biotherapy & Radiopharmaceuticals, 18, 525-33
ISSN: 1084-9785
Popis: Item does not contain fulltext Radioimmunotherapy (RIT) is a new and effective treatment modality in patients with non-Hodgkin's lymphoma. The monoclonal antibody (mAb) hLL2 (epratuzumab), a humanized mAb directed against the CD22 antigen, and which internalizes, can be labeled with various radionuclides. The biodistribution of hLL2 labeled with (131)I, (186)Re, (177)Lu, and (88)Y was studied in nude mice with subcutaneous human lymphoma xenografts in order to determine the most suitable of these four radionuclides for RIT with hLL2. METHODS: Human Ramos lymphoma xenografts were transplanted in cyclophosphamide-pretreated athymic BALB/c mice. Four groups of mice were injected intravenously with (131)I-, (186)Re-, (88)Y-, or (177)Lu-labeled hLL2, respectively. To determine the nonspecific tumor uptake, two groups of mice received (88)Y-labeled or (131)I-labeled control antibody, cG250. The biodistribution of the radiolabel was determined 1, 3, and 7 days postinjection (p.i.). RESULTS: Radiolabeled hLL2 had a higher tumor uptake than the nonspecific mAb at all time-points, irrespective of the radiolabel used. Tumor accretion of (88)Y- and (177)Lu-hLL2 was higher than tumor uptake of (131)I- and (186)Re-hLL2. Activity in the bone, represented by the femur without bone marrow, was higher for (177)Lu- and (88)Y-hLL2 than for (131)I- and (186)Re-hLL2 on day 7 p.i. CONCLUSION: The use of the residualizing radiolabels (88)Y and (177)Lu in combination with a mAb directed against an internalizing antigen resulted in higher uptake and better retention of the radiolabel in the tumor.
Databáze: OpenAIRE
Externí odkaz: